Overexpression of High Mobility Group A1 Protein in Human Uveal Melanomas: Implication for Prognosis

PLoS ONE

Volumn 8, Issue 7, 2013, Pages

  Qu, Yi ^a   Wang, Yupeng ^b   Ma, Jinlan ^a   Zhang, Yue ^a   Meng, Nana ^a   Li, Hao ^a   Wang, Yan ^a   Wei, Wenbin ^c  

^a SHANDONG UNIVERSITY   (China)

^b SHANDONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^c CAPITAL MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

HIGH MOBILITY GROUP A1 PROTEIN; HIGH MOBILITY GROUP PROTEIN; KI 67 ANTIGEN; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CANCER PROGNOSIS; CANCER SURVIVAL; CLINICAL FEATURE; DISEASE ASSOCIATION; DISTANT METASTASIS; ENZYME ACTIVITY; EPITHELIOID CELL; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MITOSIS; MULTIVARIATE ANALYSIS; PROPORTIONAL HAZARDS MODEL; PROTEIN EXPRESSION; PROTEIN FUNCTION; UVEA MELANOMA;

FEMALE; HMGA1A PROTEIN; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MELANOMA; MIDDLE AGED; NEOPLASM METASTASIS; PROGNOSIS; TUMOR MARKERS, BIOLOGICAL; UVEAL NEOPLASMS;

EID: 84880736990     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0068724     Document Type: Article

References (50)

1. Diener-West M, Hawkins BS, Markowitz JA, Schachat AP, (1992) A review of mortality from choroidal melanoma. II. A meta-analysis of 5-year mortality rates following enucleation, 1966 through 1988. Arch Ophthalmol 110: 245-250.
2. Egan KM, Seddon JM, Glynn RJ, Gragoudas ES, Albert DM, (1988) Epidemiologic aspects of uveal melanoma. Surv Ophthalmol 32: 239-251.
3. Singh AD, Topham A, (2003) Survival rates with uveal melanoma in the United States: 1973-1997. Ophthalmology 110: 962-965.
4. Johansson CC, Mougiakakos D, Trocme E, All-Ericsson C, Economou MA, et al. (2010) Expression and prognostic significance of iNOS in uveal melanoma. Int J Cancer 126: 2682-2689.
5. Kujala E, Makitie T, Kivela T, (2003) Very long-term prognosis of patients with malignant uveal melanoma. Invest Ophthalmol Vis Sci 44: 4651-4659.
6. Rietschel P, Panageas KS, Hanlon C, Patel A, Abramson DH, et al. (2005) Variates of survival in metastatic uveal melanoma. J Clin Oncol 23: 8076-8080.
7. Pyrhonen S, (1998) The treatment of metastatic uveal melanoma. Eur J Cancer 34Suppl 3: S27-30.
8. Triozzi PL, Eng C, Singh AD, (2008) Targeted therapy for uveal melanoma. Cancer Treat Rev 34: 247-258.
9. Eskelin S, Pyrhonen S, Summanen P, Hahka-Kemppinen M, Kivela T, (2000) Tumor doubling times in metastatic malignant melanoma of the uvea: tumor progression before and after treatment. Ophthalmology 107: 1443-1449.
10. Sebastian Eskelin TK, (2001) Author's reply. Ophthalmology 108: 830-831.
11. Group COMS (2001) Assessment of metastatic disease status at death in 435 patients with large choroidal melanoma in the Collaborative Ocular Melanoma Study (COMS): COMS report no. 15. Arch Ophthalmol 119: 670-676.
12. Coupland SE, Campbell I, Damato B, (2008) Routes of extraocular extension of uveal melanoma: risk factors and influence on survival probability. Ophthalmology 115: 1778-1785.
13. Damato B, Coupland SE (2009) A reappraisal of the significance of largest basal diameter of posterior uveal melanoma. Eye (Lond) 23: 2152-2160; quiz 2161-2152.
14. Folberg R, Pe'er J, Gruman LM, Woolson RF, Jeng G, et al. (1992) The morphologic characteristics of tumor blood vessels as a marker of tumor progression in primary human uveal melanoma: a matched case-control study. Hum Pathol 23: 1298-1305.
15. McLean IW, Zimmerman LE, Evans RM, (1978) Reappraisal of Callender's spindle a type of malignant melanoma of choroid and ciliary body. Am J Ophthalmol 86: 557-564.
16. Harbour JW, Onken MD, Roberson ED, Duan S, Cao L, et al. (2010) Frequent mutation of BAP1 in metastasizing uveal melanomas. Science 330: 1410-1413.
17. Prescher G, Bornfeld N, Hirche H, Horsthemke B, Jockel KH, et al. (1996) Prognostic implications of monosomy 3 in uveal melanoma. Lancet 347: 1222-1225.
18. Trolet J, Hupe P, Huon I, Lebigot I, Decraene C, et al. (2009) Genomic profiling and identification of high-risk uveal melanoma by array CGH analysis of primary tumors and liver metastases. Invest Ophthalmol Vis Sci 50: 2572-2580.
19. Van Raamsdonk CD, Griewank KG, Crosby MB, Garrido MC, Vemula S, et al. (2010) Mutations in GNA11 in uveal melanoma. N Engl J Med 363: 2191-2199.
20. Chiappetta G, Avantaggiato V, Visconti R, Fedele M, Battista S, et al. (1996) High level expression of the HMGI (Y) gene during embryonic development. Oncogene 13: 2439-2446.
21. Zhou X, Benson KF, Ashar HR, Chada K, (1995) Mutation responsible for the mouse pygmy phenotype in the developmentally regulated factor HMGI-C. Nature 376: 771-774.
22. Wood LJ, Maher JF, Bunton TE, Resar LM, (2000) The oncogenic properties of the HMG-I gene family. Cancer Res 60: 4256-4261.
23. Wood LJ, Mukherjee M, Dolde CE, Xu Y, Maher JF, et al. (2000) HMG-I/Y, a new c-Myc target gene and potential oncogene. Mol Cell Biol 20: 5490-5502.
24. Reeves R, Edberg DD, Li Y, (2001) Architectural transcription factor HMGI(Y) promotes tumor progression and mesenchymal transition of human epithelial cells. Mol Cell Biol 21: 575-594.
25. Fedele M, Pentimalli F, Baldassarre G, Battista S, Klein-Szanto AJ, et al. (2005) Transgenic mice overexpressing the wild-type form of the HMGA1 gene develop mixed growth hormone/prolactin cell pituitary adenomas and natural killer cell lymphomas. Oncogene 24: 3427-3435.
26. Xu Y, Sumter TF, Bhattacharya R, Tesfaye A, Fuchs EJ, et al. (2004) The HMG-I oncogene causes highly penetrant, aggressive lymphoid malignancy in transgenic mice and is overexpressed in human leukemia. Cancer Res 64: 3371-3375.
27. Fusco A, Fedele M, (2007) Roles of HMGA proteins in cancer. Nat Rev Cancer 7: 899-910.
28. Mu G, Liu H, Zhou F, Xu X, Jiang H, et al. (2010) Correlation of overexpression of HMGA1 and HMGA2 with poor tumor differentiation, invasion, and proliferation associated with let-7 down-regulation in retinoblastomas. Hum Pathol 41: 493-502.
29. Shah SN, Resar LM, (2012) High mobility group A1 and cancer: potential biomarker and therapeutic target. Histol Histopathol 27: 567-579.
30. Takaha N, Sowa Y, Takeuchi I, Hongo F, Kawauchi A, et al. (2012) Expression and role of HMGA1 in renal cell carcinoma. J Urol 187: 2215-2222.
31. Chuma M, Saeki N, Yamamoto Y, Ohta T, Asaka M, et al. (2004) Expression profiling in hepatocellular carcinoma with intrahepatic metastasis: identification of high-mobility group I(Y) protein as a molecular marker of hepatocellular carcinoma metastasis. Keio J Med 53: 90-97.
32. Scholzen T, Gerdes J, (2000) The Ki-67 protein: from the known and the unknown. J Cell Physiol 182: 311-322.
33. Damato B, Duke C, Coupland SE, Hiscott P, Smith PA, et al. (2007) Cytogenetics of uveal melanoma: a 7-year clinical experience. Ophthalmology 114: 1925-1931.
34. McLean IW, Foster WD, Zimmerman LE, Gamel JW, (1983) Modifications of Callender's classification of uveal melanoma at the Armed Forces Institute of Pathology. Am J Ophthalmol 96: 502-509.
35. Folberg R, Rummelt V, Parys-Van Ginderdeuren R, Hwang T, Woolson RF, et al. (1993) The prognostic value of tumor blood vessel morphology in primary uveal melanoma. Ophthalmology 100: 1389-1398.
36. Wang EL, Qian ZR, Rahman MM, Yoshimoto K, Yamada S, et al. (2010) Increased expression of HMGA1 correlates with tumour invasiveness and proliferation in human pituitary adenomas. Histopathology 56: 501-509.
37. Rahman MM, Qian ZR, Wang EL, Sultana R, Kudo E, et al. (2009) Frequent overexpression of HMGA1 and 2 in gastroenteropancreatic neuroendocrine tumours and its relationship to let-7 downregulation. Br J Cancer 100: 501-510.
38. Mooy CM, de Jong PT, Van der Kwast TH, Mulder PG, Jager MJ, et al. (1990) Ki-67 immunostaining in uveal melanoma. The effect of pre-enucleation radiotherapy. Ophthalmology 97: 1275-1280.
39. Augsburger JJ, Correa ZM, Shaikh AH, (2009) Effectiveness of treatments for metastatic uveal melanoma. Am J Ophthalmol 148: 119-127.
40. Kim IK, Lane AM, Gragoudas ES, (2010) Survival in patients with presymptomatic diagnosis of metastatic uveal melanoma. Arch Ophthalmol 128: 871-875.
41. Shields CL, Ganguly A, Bianciotto CG, Turaka K, Tavallali A, et al. (2011) Prognosis of uveal melanoma in 500 cases using genetic testing of fine-needle aspiration biopsy specimens. Ophthalmology 118: 396-401.
42. Griewank KG, Murali R, (2013) Pathology and genetics of uveal melanoma. Pathology 45: 18-27.
43. Flohr AM, Rogalla P, Bonk U, Puettmann B, Buerger H, et al. (2003) High mobility group protein HMGA1 expression in breast cancer reveals a positive correlation with tumour grade. Histol Histopathol 18: 999-1004.
44. Hristov AC, Cope L, Di Cello F, Reyes MD, Singh M,et al. HMGA1 correlates with advanced tumor grade and decreased survival in pancreatic ductal adenocarcinoma. Mod Pathol 23: 98-104.
45. Sarhadi VK, Wikman H, Salmenkivi K, Kuosma E, Sioris T, et al. (2006) Increased expression of high mobility group A proteins in lung cancer. J Pathol 209: 206-212.
46. Diener-West M, Reynolds SM, Agugliaro DJ, Caldwell R, Cumming K, et al. (2004) Screening for metastasis from choroidal melanoma: the Collaborative Ocular Melanoma Study Group Report 23. J Clin Oncol 22: 2438-2444.
47. Gragoudas E, Li W, Goitein M, Lane AM, Munzenrider JE, et al. (2002) Evidence-based estimates of outcome in patients irradiated for intraocular melanoma. Arch Ophthalmol 120: 1665-1671.
48. Scala S, Portella G, Fedele M, Chiappetta G, Fusco A, (2000) Adenovirus-mediated suppression of HMGI(Y) protein synthesis as potential therapy of human malignant neoplasias. Proc Natl Acad Sci U S A 97: 4256-4261.
49. Liau SS, Jazag A, Whang EE, (2006) HMGA1 is a determinant of cellular invasiveness and in vivo metastatic potential in pancreatic adenocarcinoma. Cancer Res 66: 11613-11622.
50. Palmieri D, D'Angelo D, Valentino T, De Martino I, Ferraro A, et al. (2012) Downregulation of HMGA-targeting microRNAs has a critical role in human pituitary tumorigenesis. Oncogene 31: 3857-3865.